By Fineline Cube HutchMed (China) Limited (NASDAQ: HCM; HKG: 0013) announced today that its subsidiary, HUTCHMED Limited, has entered into an exclusive development and license agreement with a subsidiary of GSK, granting GSK worldwide rights (excluding China — Mainland, Hong Kong, Macau and Taiwan) to develop and commercialize HMPL‑A830, a first‑in‑class Antibody‑Targeted Therapy Conjugate (ATTC). The deal delivers a USD 110 million upfront payment and up to USD 1.295 billion in total potential value including development, regulatory and commercial milestones, plus royalties on net sales — one of the largest outbound oncology licensing transactions from China this year.
Deal Terms at a Glance
| Item | Detail |
|---|---|
| Parties | HUTCHMED Limited (subsidiary of HutchMed) and a subsidiary of GSK |
| Asset | HMPL‑A830, first‑in‑class ATTC |
| Rights Granted | GSK: worldwide (ex‑China) development and commercialization |
| Rights Retained | HUTCHMED: full development and commercialization rights in China; global Phase I responsibility |
| Upfront Payment | USD 110 million |
| Total Potential Value | Up to USD 1.295 billion (incl. development, regulatory and commercial milestones) |
| Royalties | On net sales |
| Additional Rights | GSK holds right of first negotiation on one earlier‑stage ATTC candidate |
Drug Profile & Mechanism of Action
- Molecule: HMPL‑A830, a first‑in‑class Antibody‑Targeted Therapy Conjugate (ATTC) drug candidate
- Design: A highly selective and potent KRAS small‑molecule inhibitor payload conjugated to an anti‑EGFR antibody
- Innovation: The ATTC platform enables tumor‑selective activity of potent, cell‑killing payloads by leveraging antibody‑guided therapy — aiming to widen the therapeutic window of KRAS inhibition
- Target Indications (Initial): Colorectal, pancreatic and lung cancers — tumor types with high unmet need and frequent KRAS/EGFR pathway involvement
- Platform Optionality: The GSK right of first negotiation on an additional earlier‑stage ATTC candidate underscores the breadth of HUTCHMED’s conjugate pipeline
Clinical Development Plan – Global Phase I
| Item | Detail |
|---|---|
| Trial Identifier | NCT07718581 (ClinicalTrials.gov) |
| Expected Start | Second half of 2026 |
| Lead Sponsor (Phase I) | HUTCHMED Limited (global program) |
| Post‑Phase I Responsibility | GSK subsidiary for all subsequent clinical development and commercialization outside China |
| China Rights | HUTCHMED retains full development and commercialization in China |
The division of labor preserves HUTCHMED’s strategic footing in its home market while shifting ex‑China execution risk and cost to GSK, whose global oncology commercial infrastructure positions HMPL‑A830 for broad international development.
Market Impact & Outlook
- Deal scale: Up to USD 1.295 billion in total consideration, anchored by USD 110 million upfront, reinforces the momentum of China‑originated oncology out‑licensing deals
- Hot target convergence: HMPL‑A830 pairs two validated oncology modalities — KRAS inhibition and EGFR‑directed delivery — in a market where KRAS‑targeted therapies are among the most actively pursued assets in solid tumors
- Pipeline validation: GSK’s right of first negotiation on a second ATTC candidate signals confidence in HUTCHMED’s conjugate platform beyond a single asset
- Financial flexibility: The upfront payment strengthens HutchMed’s balance sheet to fund its broader oncology pipeline, while retained China rights preserve a potential domestic revenue stream for HMPL‑A830
Forward‑Looking Statements — This brief contains forward‑looking statements regarding the development timeline, clinical plans, milestone achievement, and commercial potential of HMPL‑A830. Actual results may differ materially due to clinical, regulatory, competitive, and market risks. No investment decision should be made solely on the basis of this brief.-Fineline Info & Tech